Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 45,19 € (+159,41 %). La médiane est de 45,19 € (+159,41 %).
| Acheter |
6 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Semler Scientific files supplemental pro-forma financial data for merger with Strive
Semler Scientific filed amended, unaudited consolidated pro-forma financial data with the SEC for the nine months ended September 30, 2025 and for 2024 in connection with the proposed stock transaction with Strive. The company continues to emphasize customary closing conditions and cites risk factors such as bitcoin volatility, integration risks, potential delays, legal proceedings and dilution from additional Strive shares. Semler released preliminary Q3 2025 figures (revenue guidance $6.9–7.5 million; operating expenses $12.8–13.4 million), reported an unrealized fair‑value gain of about $30 million on bitcoin holdings (carrying value $575.8 million as of Sept. 30) and announced a $20 million credit facility with Coinbase Credit. » Plus sur de.investing.com
Semler Scientific uses dashboard to disclose and adjusts metrics for bitcoin strategy
Semler Scientific names bitcoin return as its key metric and reports a Q3 2025 return of 0.9% and a year-to-date return (through 10 Nov 2025) of 30.6%. The company operates a public dashboard with market data, bitcoin purchases and performance metrics and intends to use it to comply with Regulation FD. Semler warns of risks from bitcoin volatility, its treasury strategy and the health-care business and reports holding 5,048 bitcoins with an unrealized gain of about $30 million. In addition, the company provides preliminary Q3 figures (revenue guidance $6.9–7.5m, operating expenses $12.8–13.4m), a $20 million loan from Coinbase Credit secured by bitcoin and an ongoing merger with Strive, Inc. » Plus sur de.investing.com
Semler Scientific files supplemental SEC disclosure on merger with Strive
Semler Scientific said it filed a supplemental disclosure (Form 8‑K, Exhibit 99.1) related to the proposed all‑stock transaction with Strive, which remains subject to shareholder approval and customary closing conditions. The filing includes a risk warning such as possible failure of the transaction, litigation, integration challenges, dilution, and potential stock‑price and customer or employee reactions. The company also released preliminary Q3 figures (revenue guidance $6.9–7.5 million; operating expenses $12.8–13.4 million) and reported an unrealized Bitcoin gain of about $30 million; its Bitcoin holdings (5,048 BTC) were valued at $575.8 million and it took a $20 million loan from Coinbase Credit secured by Bitcoin. Benchmark cut its price target to $86 but kept its rating at Buy. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2025 | YoY |
|---|---|---|
| Chiffre d'affaires | 6,38 M | - |
| Bénéfice brut | 5,84 M | - |
| Bénéfice net | 14,4 M | - |
| EBITDA | 21,7 M | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 278,1 M € |
Nombre d'actions | 15,29 M |
Plus haut/bas sur 52 semaines | 59,05 € - 13,32 € |
| Dividendes | Non |
Bêta | 1,32 |
Ratio P/E | 2,97 |
Ratio PEG | -0,01 |
Ratio P/B | 0,66 |
Ratio P/S | 19,78 |
Profil de l'entreprise
Semler Scientific, Inc. fournit des solutions technologiques visant à améliorer l'efficacité clinique et l'efficience des prestataires de soins de santé aux États-Unis. Les produits de la société comprennent QuantaFlo, un test de débit sanguin réalisé en cabinet en quatre minutes, qui permet aux prestataires de soins de santé d'utiliser les mesures du débit sanguin dans le cadre de leurs examens de l'état vasculaire d'un patient. Ses produits s'adressent aux cardiologues, aux internistes, aux néphrologues, aux endocrinologues, aux podologues et aux médecins de famille, ainsi qu'aux régimes d'assurance maladie, aux réseaux de soins intégrés, aux groupes de médecins indépendants et aux entreprises sous contrat avec le secteur de la santé, comme les groupes d'évaluation des risques. La société commercialise ses produits par l'intermédiaire de vendeurs et de distributeurs. Semler Scientific, Inc. a été constituée en 2007 et a son siège social à Santa Clara, en Californie.
| Nom | SEMLER SCIENTIFIC |
| PDG | Douglas Murphy-Chutorian |
| Siège social | Santa Clara,
ca États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Équipements et fournitures médicaux |
| Introduction en bourse | 21/02/2014 |
| Employés | 79 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | SMLR |
Frankfurt | 6FA.F |
Düsseldorf | 6FA.DU |
München | 6FA.MU |
